亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

隨州市紅旗化工有限公司  

醫藥原料醫藥中間體原料藥

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 馬來酸桂哌齊特 CAS: 26328-04-1
馬來酸桂哌齊特 CAS: 26328-04-1
單價 面議對比
詢價 暫無
發貨 湖北隨州市付款后3天內
型號 26328-04-1
過期 長期有效
更新 2020-06-18 10:08
 
詳細信息

馬來酸桂哌齊特
CAS: 26328-04-1
中文同義詞: (E)-1-{4-[(3,4,5’-三甲氧基肉桂?;?]-1-哌嗪}乙酰吡咯啶順丁烯二禁發 鹽酸;馬來酸桂哌齊特;1-[(1-吡咯烷甲酰)甲基]-4-(3,4,5-三甲氧基肉桂?;?哌嗪順丁烯二酸鹽;馬來酸桂哌奇特
英文名稱: Cinepazide maleate
英文同義詞: 1-((1-pyrrolidinylcarbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazinem;1-(4-((3’,4’,5’-trimethoxycinnamoyl)-1-piperazinyl)acetyl)pyrrolidinemaleate;4-(3,4,5-trimethoxycinnamoyl)-1-(1-pyrrolidinyl)carbonylmethylpiperazinemale;brendil;maleatedecinepazide;md67350;piperazine,1-((1-pyrrolidinylcarbonyl)methyl)-4-(3’,4’,5’-trimethoxycinnamoyl);vasodistal
分子式: C26H35N3O9
分子量: 533.57
EINECS號: 247-613-1
熔  點:173~174°C
標準:cp標準
含量:≥99%
性狀:白色結晶性粉末
用途  腦血管疾?。耗X動脈硬化、一過性腦缺血、腦血栓、腦栓塞、腦出血及腦外傷后遺癥。心血管疾病,用于動脈硬化、心絞痛,心肌梗塞患者應配合相關藥物治療。眼底血管性疾病、缺血所致耳蝸前庭功能失調、突發性耳聾、耳鳴。.糖尿病引起的微循環障礙(糖尿病足、糖尿病視網膜病變等)。.其它外周血管性疾病:血栓閉塞性脈管炎、動脈炎、雷諾氏病、下肢動脈粥樣硬化等。
包  裝:可以根據客戶的需要進行包裝
©2025 隨州市紅旗化工有限公司 版權所有   技術支持:化工網   訪問量:31120  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |